


PRODUCT INFORMATION

Target	PD-L1
Description	Monoclonal Cell Line Derived from K562 Cells, Engineered for Stable Expression of Human PD-L1 Using Lentiviral Technology
Host Cells	K562
Uniprot ID	Q9NZQ7
Applications	FACS Data
Growth media	RPMI-1640+10% FBS+1% P.S+1% Gln+2 ug/mL Puromycin
Package	5E6 Cells/mL
Suggested Control	SKU: BME100153
Warranty and Disclaimer	1. Please inspect cells upon receipt and report any issues promptly. 2. We offer one-time replacements for issues reported within a week of receipt. 3. User-induced issues are not eligible for free replacements. 4. We do not accept liability for damages resulting from cell use, storage, or loss. 5. Feedback received more than one month after receipt will not be processed.
Storage & Shipping	Cells are shipped using dry ice and require liquid nitrogen storage for long term preservation.
Synonyms	PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1
Background	This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells; such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue; this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments; this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies; including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Usage	For research use only.



Hu_PD-L1 K562 Cell Line



-  Human IgG
-  Anti-PDL1 (durvalumab biosimilar) mAb (SKU: BME100153)

Figure 1. Flow cytometry analysis of human PD-L1 overexpression using Hu_PD-L1 K562 Cell Line (Cat. No. CEL100022) and Anti-PDL1 (durvalumab biosimilar) mAb (Cat. No. BME100153)

DIMABIO CONFIDENTIAL

